查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球神经退行性疾病市场
市场调查报告书
商品编码
1143376

2022-2029 年全球神经退行性疾病市场

Global Neurodegenerative Disease Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期间（2022-2029 年），神经退行性疾病市场规模预计将以 7.4% 的复合年增长率增长。

阿尔茨海默病、帕金森病和亨廷顿病等神经退行性疾病会影响人脑中的神经元，使其无法自我更新。因此，神经元死亡意味着永久性丧失，而这种丧失是无法替代的。

市场动态

神经退行性疾病市场的增长包括神经系统疾病患病率的上升、社会意识的提高、老年人口的增加以及神经退行性疾病治疗的强大产品线。

预计神经退行性疾病患病率的上升将推动市场增长。

随着年龄的增长，我们更有可能患上阿尔茨海默病、帕金森病和谵妄等神经退行性疾病。在预测期内，不断增长的老年人口将推动全球神经退行性疾病市场。例如，据 NIH 称，谵妄影响超过 14% 至 56% 的住院老年患者，每年有超过 1250 万 65 岁及以上的患者患有谵妄。例如，根据美国经济和社会事务局的数据，2020 年 65 岁及以上的人口数量约为 2.72 亿，预计到 2050 年将达到 15 亿。大约 9.3% 的人口是老年人，预计到 2050 年将增长到 16% 以上。

此外，45 岁以上的人中，每 10 人中就有 1 人患有主观认知能力下降，据世界卫生组织统计，全球 41% 的老年人口无法进行日常活动。世界老年人口中约有5500万人患有痴呆症，据说每年有1000万人患痴呆症。此外，据阿尔茨海默病国际组织称，到 2020 年，全球痴呆症患者人数将超过 5500 万，预计 2030 年和 2050 年将达到 7800 万和 1.39 亿。目前，人们每年因痴呆症造成的损失超过 1.3 万亿美元，预计到 2030 年将达到 2.8 万亿美元。此外，根据国际帕金森病与运动障碍协会的数据，预计2020年全球将有约940万人患上帕金森病。

严格的监管指南和专利到期预计将阻碍全球神经退行性疾病市场的增长。

然而，药物开发和神经退行性疾病治疗产品专利到期的严格监管指南是预计阻碍全球神经退行性疾病市场增长的主要因素。

行业分析

《全球神经退行性疾病市场报告》根据波特五力、创新、新产品发布、定价分析和管道分析等各种行业因素对市场进行了深入分析。

细分分析

预计帕金森病细分市场将在整个预测期内（2022-2029 年）主导神经退行性疾病市场。

预计帕金森病在预测期内将以最高的复合年增长率增长，原因是患病率上升以及对该病治疗方法的研发增加。帕金森病是继阿尔茨海默病之后第二常见的与年龄相关的神经退行性疾病。据估计，全世界约有 1000 万人患有帕金森病。患病率从生命第四年的每 100,000 人 41 人到 80 岁以上的每 100,000 人超过 1,900 人不等。根据帕金森病基金会的数据，全世界约有 1000 万人被诊断出患有帕金森病。帕金森病的风险随着年龄的增长而增加。根据帕金森病基金会的数据，帕金森病患者每年平均花费 2,500 美元用于药物治疗，每人花费近 100,000 美元用于手术干预。目前帕金森病的治疗方法包括左旋多巴和多巴胺激动剂，它们可以减少与该疾病相关的早期运动症状。然而，随着疾病的进展和神经细胞的退化，这些治疗最终对症状变得不那么有效。此外，2022 年 1 月 7 日，Alembic Pharmaceuticals 获得了美国卫生当局的最终批准，用于帕金森病患者的通用 Entacapone 片剂。

区域分析

北美地区占全球神经退行性疾病市场的最大市场份额。

由于该地区阿尔茨海默病的发病率不断上升，北美在全球神经退行性疾病市场中占据主导地位，在 2021 年占据最大的市场份额。根据阿尔茨海默病协会的数据，到 2022 年，65 岁以上的美国人将有 650 万患有阿尔茨海默病。到 2050 年，65 岁及以上患有阿尔茨海默病的人数可能会上升到 1270 万。还有数千名未被发现的患者。阿尔茨海默病是 2020 年和 2021 年美国第七大死亡原因。随着美国的老龄化，患有神经退行性疾病的人数继续增加。据帕金森基金会称，每年估计有 60,000 名美国人被诊断出患有 PD。到 2022 年底，阿尔茨海默病和其他痴呆症的成本可能达到 3210 亿美元，到 2050 年将接近 1 万亿美元。

竞争格局

神经退行性疾病市场包括 AbbVie Inc.、Amneal Pharmaceuticals Inc.、Boehringer Ingelheim International GmbH、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline PLC、Merck&Co.Inc.、Pfizer Inc.、Teva Pharmaceutical、UCB SA、Novartis和别的。领先企业正在采取各种增长战略，例如产品发布、併购、合作伙伴关係和合作，为全球神经退行性疾病市场的增长做出贡献。例如，2022 年 8 月 16 日，GlaxoSmithKline收购了 Affinivax, Inc.。 2022年5月，Pfizer同意收购Biohaven。

Novartis

概述

Novartis是一家全球领先的製药公司，总部位于瑞士巴塞尔和美国马萨诸塞州剑桥市。Novartis于 1996 年由 Ciba-Geigy 和 Sandoz 合併而成。

产品组合

Novartis的神经退行性疾病产品组合包括用于治疗帕金森病的 Nourianz（伊曲茶碱）片剂和用于治疗轻度至中度阿尔茨海默病的 EXELON(R) PATCH（卡巴拉汀透皮系统）。

全球神经退行性疾病市场报告提供对 40 多个 市场数据表、45 多个图表和 200 页（大约）的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 神经退行性疾病增加
      • 对研发的贡献
    • 约束因素
      • 严格的开发规定
      • 专利已过期
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章适应症

  • 帕金森病
  • 肌萎缩侧索硬化症
  • 阿尔茨海默氏症
  • 亨廷顿氏病
  • 其他

第 8 章按药物类型

  • N-甲基-D-天冬氨酸受体製剂
  • 选择性血清素再摄取抑製剂
  • 多巴胺抑製剂
  • 其他

第 9 章，最终用户

  • 医院和诊所
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • Novartis
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical
  • UCB SA

第 13 章数据M

简介目录
Product Code: DMPH2090

Market Overview

Neurodegenerative Disease Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.4% during the forecast period (2022-2029).

Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, among others disorders, affect the neurons in the human brain, leading to the inability of neurons to reproduce themselves. Thus, the death of neurons indicates permanent loss, which cannot be replaced.

Market Dynamics

The growth of the neurodegenerative disease market includes the rising prevalence of neurological disorders, increasing public awareness, a growing geriatric population and a strong product pipeline for neurodegenerative disease treatment.

The rising prevalence of neurodegenerative diseases is expected to drive market growth.

With the growing age, there is a high susceptibility to developing one or other neurodegenerative diseases such as Alzheimer's, Parkinson's, Delirium, Etc. The rising geriatric population drives the global neurodegenerative disease market during the forecast period. For instance, according to the NIH, delirium affects over 14-56% of hospitalized geriatric patients; over 12.5 million patients aged 65 or over yearly suffer delirium. For instance, the Department of Economics and Social Affairs United States data shows that in 2020 the number of people aged 65 and over was around 272 million, which is predicted to reach 1.5 billion by 2050. The geriatric population is around 9.3 % and is predicted to be over 16% until 2050.

Moreover, 1 in 10 people aged 45 and above suffer from Subjective Cognitive Decline, which has led to giving daily activities in 41% of the global geriatric population as per the WHO. Also, nearly 55 million global geriatric population have dementia, with 10 million cases yearly. Furthermore, according to Alzheimer's Disease International, there were over 55 million people worldwide living with dementia in 2020, and it is estimated to reach 78 million in 2030 and 139 million in 2050; the annual global cost of dementia is now above US$ 1.3 trillion and is expected to rise to US$ 2.8 trillion by 2030. In addition, International Parkinson and Movement Disorder Society data indicates that globally around 9.4 million people with Parkinson's Disease in 2020.

The stringent regulatory guidelines and patent expiry are expected to hinder global neurodegenerative disease market growth.

However, the stringent regulatory guidelines for drug development and the expiry of neurodegenerative disease treatment product patents are the major factors that are anticipated to hamper the global neurodegenerative diseases market growth.

Industry Analysis

The global neurodegenerative disease market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

Segment Analysis

The Parkinson's disease segment is expected to dominate the neurodegenerative disease market throughout the forecast period (2022-2029).

Parkinson's disease is expected to grow at the highest CAGR during the forecast period, owing to the rising prevalence of Parkinson's disease and increasing R&D for the treatment of this disease. Parkinson's disease is the second most common age-related neurodegenerative disorder after Alzheimer's. An estimated 10 million people worldwide have Parkinson's disease. The prevalence of the disease ranges from 41 people per 100,000 in the fourth decade of life to more than 1,900 people per 100,000 among those who are 80 and older. According to the Parkinson's Disease Foundation, approximately 10 million people globally are diagnosed with Parkinson's disease. The risk of Parkinson's disease increases with age. According to the Parkinson's Disease Foundation, the medication cost for a patient with the disease is, on average, USD 2,500 a year, and therapeutic surgery costs nearly USD 100,000 per person. The current treatments for Parkinson's, include levodopa and dopamine agonists, which can help manage early motor symptoms associated with the disease. However, as the disease progresses and neurons degenerate, these therapies ultimately become less effective at treating the symptoms. Furthermore, on January 7, 2022, Alembic Pharmaceuticals received final approval from the US health regulator for its generic Entacapone tablets indicated for patients with Parkinson's disease.

Geographical Analysis

The North American region holds the largest market share of the global neurodegenerative disease market.

North America is dominating the global neurodegenerative disease market, accounting for the largest market share in 2021, owing to the increasing incidence of Alzheimer's disease in this region. According to Alzheimer's Association, in 2022, 6.5 million Americans age 65 and older are living with Alzheimer's. By 2050, the number of people aged 65 and older with Alzheimer's may grow to 12.7 million. Also, there are thousands of patients who go undetected. Alzheimer's is the seventh-leading cause of death in the United States in 2020 and 2021. As the US population ages, the number of people living with neurodegenerative diseases continues to grow. An estimated 60,000 Americans are diagnosed with PD each year, as per Parkinson's Foundation. In addition, by the end of 2022, Alzheimer's and other dementias will cost the nation $321 billion, and by 2050, these costs could reach nearly $1 trillion.

Competitive Landscape

The neurodegenerative disease market is highly competitive with the presence of a large number of players, including AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical, UCB SA, Novartis, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the neurodegenerative disease market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc. Also, in May 2022, Pfizer agreed to acquire Biohaven.

Novartis AG

Overview:

Novartis AG is a leading global pharmaceutical manufacturing company based in Basel, Switzerland and Cambridge, Massachusetts, United States. Novartis AG was founded in 1996 through the merger of Ciba-Geigy and Sandoz.

Product Portfolio:

Novartis AG's product portfolio for the neurodegenerative disease has Nourianz (istradefylline) tablets for Parkinson's and EXELON® PATCH (rivastigmine transdermal system) for mild to moderate Alzheimer's.

The global neurodegenerative disease market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Neurodegenerative Diseases
      • 4.1.1.2. Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. The Stringent Developmental Regulations
      • 4.1.2.2. Patent Expiry
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Indication Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type Segment
    • 7.1.2. Market Attractiveness Index, By Indication Type Segment
  • 7.2. Parkinson's Disease
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Amyotrophic Lateral Sclerosis
  • 7.4. Alzheimer's Disease
  • 7.5. Huntington Disease
  • 7.6. Others

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 8.1.2. Market Attractiveness Index, By Drug Type Segment
  • 8.2. N-methyl-D-aspartate Receptor
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Selective Serotonin Reuptake Inhibitor
  • 8.4. Dopamine Inhibitors
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Novartis
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AbbVie Inc.
  • 12.3. Amneal Pharmaceuticals Inc.
  • 12.4. Boehringer Ingelheim International GmbH
  • 12.5. F. Hoffmann-La Roche Ltd.
  • 12.6. GlaxoSmithKline PLC
  • 12.7. Merck & Co. Inc.
  • 12.8. Pfizer Inc.
  • 12.9. Teva Pharmaceutical
  • 12.10. UCB SA

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us